Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel
"We are pleased to welcome Lori," said Keith J. Kendall, Chief Executive Officer of
Braender joins Aquestive from a 35-year career at
Ms.Braender added, "I'm honored to join the Aquestive team. The company's unique business model and technology deliver meaningful solutions to patients, and I Iook forward to contributing the success of these efforts."
About
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "project," "will," "would," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. Such statements include, but are not limited to, statements about regulatory approvals and pathways, clinical trial timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, business strategies, market opportunities, financing, and other statements that are not historical facts.
These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials; the risks of delays in
Media inquiries:
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
stephanie.carrington@icrinc.com
646-277-1282
View original content to download multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-names-lori-j-braender-esq-as-senior-vice-president-general-counsel-300710098.html
SOURCE